Chia Tai Tianqing Pharmaceutical Technology Development

Chia Tai Tianqing Pharmaceutical Group (CTTQ) is a leading Chinese pharmaceutical company and a core subsidiary of Sino Biopharmaceutical. The company specializes in the research, development, and manufacturing of a wide range of therapeutic products, with a dominant market position in liver disease and oncology. CTTQ's portfolio includes innovative small molecules and biologics, such as the multi-target kinase inhibitor anlotinib. Headquartered in Lianyungang, Jiangsu, the company operates extensive R&D facilities and manufacturing sites, consistently ranking among the top innovative pharmaceutical firms in China. The company is increasingly focused on transitioning from a generic-heavy portfolio to one driven by innovative biopharmaceuticals and global partnerships.